Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, may elicit anti-tumor results in various

Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, may elicit anti-tumor results in various malignancies. Cisplatin-based chemotherapy is the standard treatment for patients with metastatic UC [3], [4]; however, despite regimens such as the cisplatin, gemcitabine or paclitaxel combination, the overall response rates vary between 40% and 65% [5], [6]. Most patients eventually die of metastatic disease and… Continue reading Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, may elicit anti-tumor results in various